간행물

생화학분자생물학회입니다.


EMM

Exploring the potential of Toxoplasma gondii as a drug development and delivery system

  • 작성자

    Chul-Su Yang
  • 작성일자

    2024-03-22
  • 조회수

    1193
Chul-Su Yang( chulsuyang@hanyang.ac.kr )
2014-presentAssistant / Associate / Professor,
Dept. of Medicinal and Life Science, Hanyang University, South Korea
2012-2014Assistant Professor, College of Medicine, Chungnam National University, South Korea
2009-2012Research Associate, Dept. of Molecular Microbiology & Immunology
Keck School of Medicine, University of Southern California, USA
2004-2008PhD, Dept. of Microbiology, College of Medicine, Chungnam National University, South Korea
2000-2004MS, Dept. of Microbiology, College of Natural Sciences, Chungnam National University, South Korea

Exploring the potential of Toxoplasma gondii as a drug development and delivery system

Immune-mediated inflammatory diseases are various groups of conditions that result in immune system disorders and increased development of cancer risk. Despite the identification of causative cytokines and pathways, current clinical treatment is no cure for Immune-mediated inflammatory diseases. In addition, Immune-mediated inflammatory diseases treatment can increase the risk of cancer. Several previous studies have demonstrated that Toxoplasma gondii manipulates immune response by inhibiting or stimulating cytokines suggesting the potential for control and maintaining a balanced immune system. Additionally, Toxoplasma gondii also has the unique characteristic of being a so-called “Trojan horse” strategy that can be used as a drug delivery system to treat regions that have been resistant to previous drug delivery therapies. In this study, we review the potential of Toxoplasma gondii as a drug development and delivery system by current research on inflammation-regulating mechanisms in Immune-mediated inflammatory diseases

Exp Mol Med. 2024 Feb;56(2):289-300. doi: 10.1038/s12276-024-01165-7.
https://pubmed.ncbi.nlm.nih.gov/38297164/